Moderna raised its 2026 revenue growth outlook to 15% to 25% on Friday, up from its previous guidance of up to 10%. The company also beat third-quarter revenue and earnings estimates, according to the report.
Third-quarter revenue rose 29% to $1.31 billion. Revenue was $780 million in the U.S. and $533 million in international markets. Moderna posted net income of $162 million, or 38 cents per share, compared with a net loss of $200 million, or 51 cents per share, a year earlier.
CEO Stéphane Bancel attributed the results to newer products and geographic expansion. He said the company is seeing the "full-year impact" of its next-generation mRNA Covid vaccine, which won U.S. approval in May 2025. He also said Moderna's stand-alone flu shot, approved in the U.S. in August, will have a "limited launch" in the country in 2026. Bancel said growth in Canada, the U.K. and Asia helped boost results, and that cost reductions contributed to a profit.
Moderna's shares rose roughly 3% in premarket trading. The stock has risen more than 700% this year, the report says, largely on optimism about the company's experimental personalized cancer vaccine. That vaccine, developed with Merck, showed promising late-stage data in certain melanoma patients when used with the immunotherapy Keytruda. Part of the data leaked on social media days before its scheduled presentation at a European medical conference, and investors sold the stock. Bancel called the reaction "surprising."